Evaluation of checkpoint inhibitor therapies using an MLR assay, is an exclusive webinar that will be hosted by DDW and supported by Sartorius.
It will provide valuable information for immuno-oncology research and the cancer immunotherapy drug discovery process.
The event will take place on 12 May at 3pm BST. Register here
Sartorius recognises that conventional techniques for analysis of mixed lymphocyte reaction (MLR) assays, such as ELISA and traditional flow cytometry and are often limited, as they can require the use of separate techniques and assays, for the measurement of proliferation and activation marker expression and for the measurement of cytokines. This means that manual collation of data from different techniques is required. Also, large sample volumes at protracted sample throughputs is observed.
To overcome these difficulties, Sartorius has developed a simple, high-throughput workflow, where a validated suite of reagent kits is used in conjunction with the iQue Advanced Flow Cytometry Platform, to provide a simple and flexible road map, for quantifying T cell response in an MLR assay.
In the webinar Kirsty McBain, Associate Scientist, Sartorius, will provide valuable details to immunologists investigating pharmacological reactions.
She will explain:
- How the iQue Advanced Flow Cytometry Platform and associated reagent kits can be used to quantify T cell response in MLR
- The use of the iQue MLR assay to generate pharmacological outputs for checkpoint inhibitor induced T cell activation
- The impact of checkpoint inhibitor therapeutics on inflammatory cytokine release
- She will also provide live answers to your questions